CPA
AXSM icon

Capital Performance Advisors’s Axsome Therapeutics AXSM Stock Holding History

Capital Performance Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10
Closed -$899 – 422
2024
Q3 		$899 Buy
+10
New +$873 ﹤0.01% 1956

Other funds holding AXSM

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital Performance Advisors's AXSM Position: Q4 2024 in Review

Capital Performance Advisors sold out of Axsome Therapeutics (AXSM) in Q4 2024, closing a stake of 10 shares — an estimated $899 sold.

Capital Performance Advisors first reported a position in AXSM in Q3 2024 and held it in 1 quarter. The position peaked at $899 in Q3 2024. 292 funds tracked by Wall St. Rank hold AXSM as of Q4 2024.

  • Capital Performance Advisors reported no remaining Axsome Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 10 Axsome Therapeutics shares in Q4 2024, an estimated $899.
  • Capital Performance Advisors first reported a position in Axsome Therapeutics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Axsome Therapeutics position peaked at $899 in Q3 2024.
  • 292 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.